I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Sarah Boyce Biography and Net Worth

President & CEO of Avidity Biosciences

Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

What is Sarah Boyce's net worth?: The estimated net worth of Sarah Boyce is at least $8.44 million as of December 18th, 2024. Ms. Boyce owns 265,308 shares of Avidity Biosciences stock worth more than $8,442,101 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Boyce may own. Additionally, Ms. Boyce receives a salary of $998,880.00 as President & CEO at Avidity Biosciences. Learn More about Sarah Boyce's net worth.
How old is Sarah Boyce?: Ms. Boyce is currently 52 years old. There are 7 older executives and no younger executives at Avidity Biosciences. Learn More on Sarah Boyce's age.
What is Sarah Boyce's salary?: As the President & CEO of Avidity Biosciences, Inc., Ms. Boyce earns $998,880.00 per year. Learn More on Sarah Boyce's salary.
How do I contact Sarah Boyce?: The corporate mailing address for Ms. Boyce and other Avidity Biosciences executives is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. Avidity Biosciences can also be reached via phone at 858-401-7900 and via email at [email protected]. Learn More on Sarah Boyce's contact information.
Has Sarah Boyce been buying or selling shares of Avidity Biosciences?: During the last ninety days, Sarah Boyce has sold $1,040,384.30 of Avidity Biosciences stock. Most recently, Sarah Boyce sold 31,855 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $32.66, for a transaction totalling $1,040,384.30. Following the completion of the sale, the chief executive officer now directly owns 265,308 shares of the company's stock, valued at $8,664,959.28. Learn More on Sarah Boyce's trading history.
Who are Avidity Biosciences' active insiders?: Avidity Biosciences' insider roster includes Sarah Boyce (President & CEO), W. Flanagan (Insider), Arthur Levin (Insider), Michael MacLean (Chief Financial and Chief Business Officer), Teresa Mccarthy (Insider), and Tamar Thompson (Director). Learn More on Avidity Biosciences' active insiders.
Are insiders buying or selling shares of Avidity Biosciences?: During the last year, insiders at the biotechnology company sold shares 36 times. They sold a total of 988,429 shares worth more than $33,473,368.19. The most recent insider tranaction occured on December, 18th when insider W. Michael Flanagan sold 12,742 shares worth more than $416,153.72. Insiders at Avidity Biosciences own 3.7% of the company. Learn More about insider trades at Avidity Biosciences.
Information on this page was last updated on 12/18/2024.

Sarah Boyce Insider Trading History at Avidity Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/18/2024	Sell	31,855	$32.66	$1,040,384.30	265,308
9/23/2024	Sell	32,880	$44.00	$1,446,720.00	234,663
8/6/2024	Sell	28,000	$43.35	$1,213,800.00	205,043
7/9/2024	Sell	28,000	$39.93	$1,118,040.00	205,043
6/13/2024	Sell	164,233	$40.08	$6,582,458.64	112,117
6/4/2024	Sell	28,000	$27.42	$767,760.00	112,117
5/7/2024	Sell	28,000	$25.54	$715,120.00	112,117
3/12/2024	Sell	28,000	$22.63	$633,640.00	112,117
3/8/2024	Sell	84,000	$21.39	$1,796,760.00	112,117
1/22/2024	Sell	5,092	$10.13	$51,581.96	44,008
2/3/2023	Sell	3,221	$24.26	$78,141.46	53,352
2/1/2023	Sell	900	$24.27	$21,843.00	53,352
8/25/2022	Sell	14,855	$23.07	$342,704.85
8/15/2022	Sell	100	$22.47	$2,247.00

Sarah Boyce Buying and Selling Activity at Avidity Biosciences

Avidity Biosciences Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $31.82

$30.85

$32.63

50 Day Range

MA: $42.38

$30.70

$52.50

2 Week Range

Now: $31.82

$8.49

$56.00

Volume

2,906,533 shs

Average Volume

1,316,742 shs

Market Capitalization

$3.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Sarah Boyce Biography and Net Worth

What is Sarah Boyce's net worth?

How old is Sarah Boyce?

What is Sarah Boyce's salary?

How do I contact Sarah Boyce?

Has Sarah Boyce been buying or selling shares of Avidity Biosciences?

Who are Avidity Biosciences' active insiders?

Are insiders buying or selling shares of Avidity Biosciences?